Toward Ultimate Care for Graves’ Hyperthyroidism


avatar Fereidoun Azizi ORCID 1 , * , avatar Hengameh Abdi 1

Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

how to cite: Azizi F, Abdi H. Toward Ultimate Care for Graves’ Hyperthyroidism. Int J Endocrinol Metab. 2020;18(1):e98255.


  • 1.

    Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, et al. Antithyroid drugs-the most common treatment for Graves' disease in the United States: A nationwide population-based study. Thyroid. 2016;26(8):1144-5. [PubMed ID: 27267495].

  • 2.

    Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol (Oxf). 2016;84(1):115-20. [PubMed ID: 25581877].

  • 3.

    Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-421. [PubMed ID: 27521067].

  • 4.

    Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J. 2018;7(4):167-86. [PubMed ID: 30283735]. [PubMed Central ID: PMC6140607].

  • 5.

    Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev. 2010;(1). CD003420. [PubMed ID: 20091544]. [PubMed Central ID: PMC6599817].

  • 6.

    Kitahara CM, Berrington de Gonzalez A, Bouville A, Brill AB, Doody MM, Melo DR, et al. Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med. 2019. [PubMed ID: 31260066]. [PubMed Central ID: PMC6604114].

  • 7.

    Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: Comparison with radioiodine. Eur J Endocrinol. 2005;152(5):695-701. [PubMed ID: 15879354].

  • 8.

    Laurberg P, Berman DC, Andersen S, Bulow Pedersen I. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. Thyroid. 2011;21(9):951-6. [PubMed ID: 21834677].

  • 9.

    Orgiazzi J. Should protracted treatment with antithyroid drug (ATD) be considered as a routine strategy in patients with Graves’ disease who had a relapse after a first course of ATD? Clin Thyroidol. 2015;27(11):302-5.;27.302-305.

  • 10.

    Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS. Outcomes in relapsed Graves' disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid. 2015;25(12):1282-90. [PubMed ID: 26414885].

  • 11.

    Chen DY, Jing J, Schneider PF, Chen TH. Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hyperthyroidism. Nucl Med Commun. 2009;30(2):160-8. [PubMed ID: 19194213].

  • 12.

    Azizi F, Malboosbaf R. Long-term antithyroid drug treatment: A Systematic review and meta-analysis. Thyroid. 2017;27(10):1223-31. [PubMed ID: 28699478].

  • 13.

    Azizi F, Malboosbaf R. Safety of long-term antithyroid drug treatment? A systematic review. J Endocrinol Invest. 2019;42(11):1273-83. [PubMed ID: 31134536].

  • 14.

    Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C; French Childhood Graves' Disease Study Group. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: National long-term cohort study. J Clin Endocrinol Metab. 2012;97(1):110-9. [PubMed ID: 22031519].

  • 15.

    Sato H, Minagawa M, Sasaki N, Sugihara S, Kazukawa I, Minamitani K, et al. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: Efficacy and adverse reactions during initial treatment and long-term outcome. J Pediatr Endocrinol Metab. 2011;24(5-6):257-63. [PubMed ID: 21823520].

  • 16.

    Yasuda K, Miyoshi Y, Tachibana M, Namba N, Miki K, Nakata Y, et al. Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves' disease. Clin Pediatr Endocrinol. 2017;26(1):1-7. [PubMed ID: 28203042]. [PubMed Central ID: PMC5295245].

  • 17.

    Azizi F, Amouzegar A, Tohidi M, Hedayati M, Khalili D, Cheraghi L, et al. Increased remission rates after long-term methimazole therapy in patients with Graves' Disease: Results of a randomized clinical trial. Thyroid. 2019;29(9):1192-200. [PubMed ID: 31310160].

  • 18.

    Azizi F, Takyar M, Madreseh E, Amouzegar A. Long-term methimazole therapy in juvenile Graves' disease: A randomized trial. Pediatrics. 2019;143(5). [PubMed ID: 31040197].